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ABSTRACT		Triptolide	 is	 a	 Chinese	 herb	 that	 has	 been	 shown	 to	 induce	 apoptosis	 in	 various	 tumor	 cells.	We	 have	previously	demonstrated	that	triptolide	induces	lysosomal-mediated	apoptosis	in	MCF-7	breast	cancer	cells.	These	findings	are	significant	because	MCF-7	cells	lack	caspase-3,	a	key	executioner	caspase,	causing	them	to	 be	 resistant	 to	 chemotherapeutics.	 In	 the	 present	 study,	 we	 examine	 whether	 triptolide	 can	 induce	apoptosis	 by	 targeting	 lysosomes	 and	 mitochondria.	 The	 effects	 of	 triptolide	 on	 lysosomal	 membrane	integrity,	subcellular	localization	of	cathepsin	B,	mitochondrial	localization,	and	mitochondrial	membrane	permeabilization	 in	 MCF-7	 cells	 were	 assessed	 via	 fluorescence	 microscopy.	 Acridine	 orange	 staining	demonstrated	 that	 triptolide	 caused	 rupture	 of	 lysosomal	membranes.	 This	 effect	 on	 disruption	 of	 the	lysosomal	 membrane	 was	 confirmed	 by	 immunofluorescent	 detection	 of	 cathepsin	 B	 in	 the	 cytosol.	MitoTracker	Green	staining	revealed	mitochondria	limited	to	the	cytosol	in	control	cells	while	mitochondria	were	 observed	 in	 nuclear	 regions	 in	 experimental	 cells.	 Triptolide	 caused	 depolarization	 of	 the	mitochondrial	membrane,	as	assessed	by	JC-1	staining.	Taken	together,	our	results	demonstrate	for	the	first	time	in	MCF-7	cells	that	triptolide	induces	apoptosis	by	lysosomal-	and	mitochondrial-dependent	pathways.	Our	 study	 provides	 a	 mechanism	 that	 may	 be	 used	 to	 develop	 novel	 breast	 cancer	 therapies	 wherein	triptolide	sensitizes	resistant	breast	cancer	cells	to	cell	death.	
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INTRODUCTION	Triptolide	(TPL)	is	a	woody	vine	widely	distributed	in	Eastern	and	Southern	China	and	the	bioactive	compo-nent	of	Tripterygium	wilfordii	Hook	F.	It	has	been	used	
in	Traditional	Chinese	Medicine	to	treat	anti-inflam-matory	and	autoimmune	disorders	for	over	two	cen-turies.	 It	has	been	shown	to	have	potent	anticancer	effects,	reviewed	in	the	following	reports	[1-4].	Breast	cancer	is	the	deadliest	malignancy	in	women	globally	[5,6].	 However,	 it	 also	 affects	 men	 [7,8],	 the	transgendered	 [9,10],	 and	 people	 from	 all	 racial	 and	ethnic	backgrounds	[11,12].	Clearly	there	is	a	dire	need	for	more	effective	treatments	against	breast	cancer.	We	have	previously	shown	that	TPL	has	immunosup-pressive,	 anti-inflammatory,	 and	anticancer	proper-ties	[13].	We	demonstrated	that	triptolide	induces	cell	death	in	MCF-7	cells	by	activating	pro-apoptotic	pro-teins	(caspases-7,	caspase-9,	and	PARP)	and	upregu-lating	 cathepsin	 B	 expression	 in	 cytosolic	 fractions	[14].	Our	prior	studies	suggest	that	TPL	is	a	lysosomo-tropic	agent	that	triggers	the	translocation	of	lysoso-mal	hydrolases	to	the	cytosol,	and	that	this	event	ini-tiates	the	intrinsic	apoptotic	pathway	[13,14].	However,	the	molecular	mechanisms	responsible	for	the	regu-lation	of	TPL	lysosomal	cell	death	have	yet	to	be	elu-cidated.	In	this	report,	lysosomal	membrane	permeabilization	and	subsequent	cytosolic	localization	of	cathepsin	B	were	detected	as	a	result	of	exposure	to	TPL.	Further-
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more,	we	demonstrate	that	TPL	induces	morphologi-cal	alterations	in	mitochondria	and	changes	in	mito-chondrial	membrane	potential.	These	results	suggest	that	TPL	 is	a	 lysosomotropic	agent	 that	 can	 initiate	the	 intrinsic,	 mitochondrial	 apoptotic	 pathway.	 To	our	knowledge,	this	reports	the	first	link	between	ly-sosomal	membrane	permeabilization	(LMP)	and	mi-tochondrial	 outer	 membrane	 permeabilization	(MOMP)	for	triptolide’s	anticancer	effects.	
Materials	and	Methods:	
Materials:	Triptolide	(C20H24O6,	MW	360.4,	95%	pu-rity)	was	purchased	from	Calbiochem	(Billerica,	MA)	and	dissolved	in	dimethyl	sulfoxide	(DMSO)	(Sigma,	St	Louis,	MO).	Stock	solutions	of	 triptolide	 in	DMSO	were	stored	at	−20°C	at	a	concentration	of	1	mg/mL.	For	all	control	experiments,	cells	were	 treated	with	vehicle,	DMSO,	as	indicated.	
Cell	Culture:	MCF-7	cells	were	purchased	from	ATCC	(Manassas,	VA).	Cells	were	grown	in	Minimum	Essen-tial	 Medium	 (Lonza	 Inc,	 Allendale,	 NJ)	 and	 supple-mented	 with	 100	 U/mL	 penicillin	 and	 100	 µg/mL	streptomycin,	 and	 10%	 FBS	 (Atlanta	 Biologicals,	Flowery	Branch,	GA).	Cells	were	incubated	at	37°C	in	a	humidified	chamber	with	95%	O2/5%	CO2.	
Acridine	 Orange:	 Cells	 were	 grown	 on	 coverslips	and	incubated	for	24	hr	±	10	nM	triptolide.	Stock	so-lutions	of	acridine	orange	were	prepared	(5	mg/mL).	Cells	were	incubated	for	15	min	in	the	dark	with	acri-dine	orange	(final	concentration,	2.5	μg/mL)	at	37°C.	Cells	were	 then	rinsed	with	1	×	PBS	and	coverslips	were	mounted	using	Crystal	Mount	(Sigma-Aldrich).	Images	were	 captured	 using	 a	Motic	 AE31	 fluores-cence	 microscope	 (British	 Columbia,	 Canada)	 and	SPOT	Imaging	Software	(Ver.	4.7.0.35).	
Immunocytochemistry:	MCF-7	cells	were	incubated	with	10	nM	 triptolide	 for	24	hr	 at	 37°C.	 Cells	were	fixed	 with	 4%	 paraformaldehyde	 in	 1X	 PBS.	 Cells	were	washed	3	times	for	5	min	at	room	temperature	and	permeabilized	with	0.2%	Triton	X-100	for	10	min	at	room	temperature.	Slides	were	washed	three	times	with	 1X	 PBS	 for	 5	 min	 and	 blocked	 using	 10%	FBS/PBS	at	room	temperature	for	40	min.	Cells	were	treated	with	a	cathepsin	B	primary	antibody	(Abcam,	Cambridge,	MA)	diluted	 in	10%	FBS/PBS	and	 incu-bated	overnight	at	4°C.	Cells	were	washed	3	times	in	1X	PBS	for	5	min	on	a	shaker	at	room	temperature.	Slides	were	then	incubated	for	1	hr	at	room	tempera-ture	 with	 a	 TRITC-conjugated	 secondary	 antibody	(Life	 Technologies,	 Grand	 Island,	NY).	 Images	were	captured	 using	 a	 Motic	 AE31	 fluorescence	 micro-scope	(British	Columbia,	Canada)	and	SPOT	Imaging	Software	(Ver.	4.7.0.35).	
Hoechst	Staining:	MCF-7	cells	were	treated	±	10	nM	triptolide	for	24	hr	at	37°C	and	then	with	1	mg/mL	of	the	 DNA	 fluorochrome	 bisbenzimide	 (Hoechst	33258;	Sigma-Aldrich)	for	15	min	at	37°C	in	the	dark.	
Assessment	 of	 Mitochondrial	 Membrane	 Poten-
tial:	 Mitochondrial	 membrane	 potential	 was	 as-sessed	 using	 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetrae-thylbenzimidazolylcarbocyanine	 iodide	 (JC-1;	 Cell	Technology,	Minneapolis,	MN).	 	 JC-1	 is	 a	mitochon-dria-specific	lipophilic	cationic	fluorescence	dye	[15].	MCF-7	cells	were	treated	±	10	nM	triptolide	for	24	hr	at	37°C	and	then	incubated	at	37°C	with	10	μg/mL	JC-1	 in	 fresh	medium	 for	30	min	and	washed	with	1X	PBS.	
Mitochondrial	Localization:	Mitochondria	in	MCF-7	cells	 were	 labeled	 using	 the	 mitochondria-specific	probe,	 MitoTracker	 Green	 (MTG),	 according	 to	 the	manufacturer’s	protocol	(Molecular	Probes,	Eugene,	OR).	Stock	solutions	of	MTG	(1	mM)	were	prepared	in	DMSO	and	stored	at	-20°C	until	needed.	MCF-7	cells	were	 grown	 to	 confluency	 in	 6-well	 plates	 and	treated	±	10	nM	triptolide	for	24	hr	at	37°C.	Then	cells	were	incubated	in	50	nM	of	MTG	in	fresh	medium	at	37°C	for	30	min	in	the	dark,	followed	by	fluorescence	microscopy.	
RESULTS	
Effect	 of	TPL	on	 lysosomal	membrane	 integrity:	To	determine	whether	TPL	induces	apoptosis	by	dis-integrating	 the	 lysosomal	 membrane,	 cells	 were	stained	with	 the	 lysosomotropic	 agent	 acridine	 or-ange,	which	 emits	 bright	 red	 fluorescence	 in	 acidic	organelles	and	green	fluorescence	in	the	nucleus	and	cytosol.	 Control	 cells	displayed	distinct	 red	 fluores-cence	in	an	acidic	environment,	lysosomes,	and	weak,	green	fluorescence	in	a	neutral	environment,	the	cy-tosol,	 (Figure	 1B).	 	In	 contrast,	 experimental	 cells	showed	reduced	red	fluorescence	and	green	fluores-cence	was	maximally	increased	(Figure	1D).		Further-more,	while	 control	 cells	 had	 a	majority	 of	 healthy	and	 adherent	 cells	 (Figure	 1A),	 experimental	 cells	displayed	 characteristic	 apoptotic	 morphology,	 in-cluding	 cell	 shrinkage	 and	 cell	 detachment	 (Figure	1C).	Our	data	indicate	that	triptolide	treatment	com-promised	 the	 lysosomal	 membrane	 and	 induced	apoptosis	by	disrupting	the	integrity	of	the	lysosomal	membrane.	
 
Figure 1: Effect of triptolide on localization of lyso-
somes. MCF-7 cells, either control cells (A and B) or 
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treated with 10 nM triptolide for 24 h to induce apop-
tosis (C and D) were stained with acridine orange for 
30 min. Shown are representative images of three in-
dependent experiments. Magnification: 400X. The 
scale bar represents 50 µm. 
TPL	modulates	the	subcellular	localization	of	ca-
thepsin	 B:	 We	 sought	 to	 determine	 whether	 trip-tolide	 causes	 translocation	 of	 lysosomal	 hydrolases	from	 the	 lysosomal	 lumen	 into	 the	 cytosol.	 To	 this	end,	we	conducted	immunocytochemistry	studies	to	examine	the	effects	of	triptolide	on	the	subcellular	lo-calization	of	cathepsin	B	in	MCF-7	cells.	Control	cells	showed	a	predominant	lysosomal	localization	of	ca-thepsin	B	(Figure	2C).	In	contrast,	experimental	cells	displayed	 predominantly	 cytosolic	 accumulation	 of	the	 enzyme	 (Figure	 2F).	 Additionally,	 control	 cells	displayed	a	weak,	punctate	red	fluorescence	staining	pattern	(Figure	2C)	compared	to	cells	exposed	to	trip-tolide,	which	exhibited	a	generalized,	diffuse	staining	pattern	(Figure	2F).	These	results	are	consistent	with	what	we	previously	reported	[14].	Furthermore,	these	findings	 indicate	 that	 triptolide	 is	 a	 lysosomotropic	agent.	
 
Figure 2: Subcellular distribution of cathepsin B.  MCF-
7 in control cells (A-C) or cells treated with 10 nM trip-
tolide (D-F) for 24 h. Cells were subjected to immuno-
cytochemistry for cathepsin B. Nuclei were stained 
with Hoechst. Arrows indicate leakage of cathepsin B 
from the lysosomes into the cytosol. Shown are repre-
sentative images of three independent experiments. 
Magnification: 400X. The scale bar represents 50 μm.	
Effect	of	TPL	on	mitochondrial	morphology:	It	was	our	aim	to	examine	the	morphology	of	mitochondria	during	this	atypical	cell	death	triggered	by	triptolide	because	evidence	 from	several	 reports	 suggest	 that	LMP	 is	 upstream	 of	MOMP	 [16,17].	 To	 observe	mito-chondria,	 cells	 were	 exposed	 to	 MTG.	 An	 image	 of	MCF-7	cells	stained	with	MTG	is	shown	in	Figure	3.	In	control	cells	MTG	staining	was	restricted	to	the	cyto-sol	(Figure	3A,	top	left	and	bottom	left	panels).	In	con-trast,	 experimental	 cells	 displayed	 a	 dramatic	 in-crease	in	green	fluorescence	that	extended	into	nuclei	(Figure	 3B,	 bottom	 left	 panel).	 Taken	 together,	 the	
data	suggest	that	triptolide	alters	the	mitochondrial	membrane.	
TPL	 regulation	 of	mitochondrial	membrane	 po-
tential:	In	light	of	our	MTG	data,	we	wanted	to	deter-mine	whether	 triptolide	had	an	effect	on	mitochon-drial	membrane	potential	 in	MCF-7	cells.	Mitochon-drial	 membrane	 potential	 (Δψm)	 changes	 were	 as-sessed	 using	 the	 fluorochrome	 JC-1.	 Control	 cells	showed	a	high	concentration	of	the	dye	(red	fluores-cence;	 Figure	 4A,	 top	 left	 panel).	 Merged	 images	demonstrate	that	treated	cells	displayed	reduced	red	fluorescence	and	increased	green	fluorescence	(Fig-ure	 4B,	 top	 right	 panel).	 In	 addition,	 experimental	cells	 displayed	 hallmarks	 of	 apoptotic	morphology,	namely,	 cell	 detachment,	 cell	 shrinkage,	 apoptotic	bodies,	and	blebbing	(Figure	4B,	bottom	right	panel).	In	contrast,	control	cells	exhibited	the	adherent	mor-phology	characteristic	of	wild-type	MCF-7	cells	(Fig-ure	 4A,	 bottom	 right	 panel).	 These	 results	 indicate	that	triptolide	treatment	causes	membrane	depolari-zation	in	mitochondria	and	apoptosis.	
	
 
Figure 3: Morphological appearance of mitochondria. 
MCF-7 cells, either control (A) or treated with 10 nM 
triptolide (B) for 24 h to induce apoptosis, were 
stained with MitoTracker Green for 15 min. Shown 
are representative images of three independent ex-
periments. Magnification: 400X. The scale bar repre-
sents 50 μm.	There	 are	 no	 clear	 guidelines	 on	 management	 of	metastatic	 neuroendocrine	 breast	 tumors.	 Initially	they	were	managed	with	 a	mastectomy	 along	with	axillary	 dissection,	 lumpectomy	 alone.	 There	 have	been	 significant	 developments	 in	 drug	 therapy	 of	
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advanced	 NETs.	 Long	 acting	 octreotide,	 m-TOR	inhibitors	 (everolimus),	 and	 VEGF	 tyrosine	 kinase	inhibitors	 (sunitinib)	 are	 becoming	 standard	treatments	 for	 patients	 with	 advanced	 NETs.	 So,	accurate	diagnosis	of	metastatic	NET	is	of	paramount	importance.	
	
 
Figure 4: Mitochondrial membrane potential. Cells 
were treated in the absence (A) or presence (B) of 10 
nM triptolide for 24 h prior to staining with JC-1. Red 
fluorescence indicates the JC-1 aggregate in healthy 
mitochondria, while green fluorescence indicates cy-
tosolic JC-1 monomers. Merged images indicated the 
co-localization of JC-1 aggregates and monomers. Im-
ages shown are representative observations from 
three independent experiments. The scale bar repre-
sents 50 µm.	
DISCUSSION	MCF-7	cells	represent	an	ideal	model	system	to	study	apoptosis-resistant	breast	cancer	cells	because	they	are	caspase	-3	deficient	[18].	Triptolide	has	potent	an-titumor	effects	both	in	vitro	[19,20]	and	in	vivo	[21,22].	We	have	previously	shown	that	triptolide	triggers	lysoso-mal-mediated	cell	death	 in	MCF-7	cells	 [14,23].	 In	 the	current	study,	we	found	that	triptolide	treatment	se-lectively	destabilized	 lysosomes	 (Figure	1D),	 induc-ing	 LMP	 in	MCF-7	 cells.	 Acridine	 orange	 is	 used	 to	specifically	label	and	identify	lysosomes	[24].	Acridine	orange	has	been	reported	to	be	selectively	retained	in	dying	 cells	 presumably	due	 to	 alterations	 in	 pH	 [25]	We	also	investigated	the	effects	of	triptolide	on	lyso-somal	membrane	 integrity	 and	 subcellular	 localiza-tion	of	cathepsin	B.	Additionally,	we	showed	that	ca-thepsin	B	was	released	from	lysosomes	and	translo-cated	into	the	cytosol.	Our	experiments	confirm	that	triptolide	is	a	lysosomotropic	agent	that	induces	cell	
death	in	an	apoptosis-resistant	tumor	cell	line,	MCF-7	 cells.	Our	 findings	 are	 in	 agreement	with	 a	 study	that	demonstrated	that	triptolide	disrupts	the	lysoso-mal	membrane	by	downregulating	Hsp70	expression	in	lysosomes	[26].	The	mechanism	by	which	triptolide	decreases	 Hsp70	 expression	 was	 shown	 to	 be	 de-pendent	on	activation	of	miR-142-3p,	a	negative	reg-ulator	of	Hsp70	[27].	Several	reports	are	investigating	the	 efficacy	 of	 lysosomotropic	 compounds	 as	 anti-cancer	therapeutics	in	clinical	trials	[28-31].		Our	results	demonstrate	that	triptolide	triggers	mito-chondrial	 membrane	 depolarization	 and	 are	 in	 ac-cordance	with	other	reports	confirming	the	ability	of	triptolide	 to	 affect	 changes	 to	 the	 mitochondrial	membrane.	One	study	showed	that	triptolide	signifi-cantly	 activated	 mitochondrial	 permeability	 transi-tion	in	liver	cells	 [32].	Another	study	found	that	trip-tolide	 induced	 depolarization	 of	 the	 mitochondrial	membrane	in	a	murine	pituitary	cancer	cell	line	[33].	A	recent	study	identified	that	triptolide-induced	cardi-otoxicity	was	due,	in	part,	to	disruption	of	the	mito-chondrial	 membrane	 [34].	 Triptolide	 was	 shown	 in	several	reports	 to	 trigger	apoptosis	by	depolarizing	mitochondrial	membrane	potential	and	releasing	of	cytochrome	 c	 from	 the	mitochondria	 to	 the	 cytosol	[35,36].			The	majority	of	anticancer	drugs	that	are	used	clini-cally	 induce	 apoptosis	 by	 activating	 signaling	 path-ways	 that	 lie	upstream	of	mitochondria	 [37-40].	Mito-chondrial	 outer	 membrane	 permeabilization	(MOMP)	is	known	to	play	a	pivotal	role	in	the	intrin-sic	 apoptotic	 pathway	 [41,42].	 MOMP	 is	 the	 critical	event	that	regulates	the	release	of	pro-apoptotic	pro-teins	 from	 the	mitochondrial	 intermembrane	 space	to	the	cytosol,	which	engage	the	caspases	to	execute	the	intrinsic	apoptotic	cascade	[43,44].	We	therefore	ex-amined	 the	effects	of	 triptolide	on	MOMP	 in	MCF-7	cells.	 Triptolide	 exposure	 induced	MOMP	 in	MCF-7	cells	as	indicated	by	the	loss	of	Δψm.	We	postulate	that	TPL-induced	 LMP	 causes	 lysosomal	 release	 of	 ca-thepsin	B	into	the	cytosol	and	induces	MOMP,	even-tually	leading	to	mitochondrial	apoptosis.	We	 propose	 that	 triptolide-induced	 lysosomal	 cell	death	is	a	viable	approach	to	circumvent	chemother-apy-	and	radiation	therapy-resistant	tumor	cells.	Ne-oplastic	 cells	 become	 resistant	 by	 upregulating	growth	promoting	genes	while	 inhibiting	pro-apop-totic	 genes.	 However,	 the	 lysosomes	 of	 tumor	 cells	have	unique	characteristics	that	are	not	present	in	ly-sosomes	 of	wild-type	 cells.	 Specifically,	 tumor	 cells	have	larger,	more	active	lysosomes	compared	to	nor-mal	cells,	which	make	them	more	vulnerable	to	lyso-somal	 membrane	 destabilization	 [45].	 Furthermore,	cancer	cells	exhibit	higher	metabolic	rates	and	turno-ver	of	iron-containing	proteins	that	sensitize	them	to	reactive	oxygen	species-induced	LMP	[46].	A	recent	re-port	demonstrated	that	an	antihistaminergic	LMP-in-ducing	 drug	 eradicated	 glioblastoma	 cells	 and	 sec-
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ondary	tumors	in	the	brain	of	mice	[47].	Clearly,	induc-ing	disruption	of	lysosomal	membranes	is	an	attrac-tive	 subcellular	 approach	 for	 designing	 novel	 anti-cancer	treatment	modalities.		The	majority	of	conventional	cancer	treatment	proto-cols	are	nonspecific,	namely	killing	tumor	cells	as	well	as	rapidly	dividing	healthy	cells	[48-51].	Clearly,	the	de-sign	of	targeted,	safer	anticancer	agents	is	warranted.	Therefore,	we	propose	that	targeting	the	lysosomal-	mitochondrial	axis	should	allow	for	the	identification	of	novel	antitumor	therapies.	Triptolide	is	an	attrac-tive	natural	anticancer	molecule	that	can	specifically	target	 canonical	 apoptosis-resistant	 tumors.	 Addi-tionally,	this	study	and	others	have	shown	that	trip-tolide	induces	apoptosis	by	impairing	mitochondrial	function.	Further	studies	are	warranted	to	elucidate	the	precise	mechanisms	by	which	triptolide	mediates	lysosomal	and	mitochondrial	dependent	cell	death	in	cancer	cells.	
CONCLUSION	In	summary,	our	results,	for	the	first	time,	illustrate	a	link	between	lysosomal	and	mitochondrial	pathways	in	TPL-induced	cell	death	of	MCF-7	cells.	This	work	contributes	to	a	better	understanding	of	how	TPL	can	be	utilized	to	target	these	organelles	as	a	novel	anti-cancer	strategy.	
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